Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | AOC2 | O75106 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | PAM | P19021 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5618233 | 1.00 | BTN3A1 (0.47) | BTN3A1CES1CES2AKR1B1TSHR | |
| SCHEMBL10727744 | 1.00 | BTN3A1 (0.47) | BTN3A1CES1CES2AKR1B1TSHR | |
| SCHEMBL27912802 | 0.86 | CES1 (0.46) | CES1CES2AKR1B1TSHRALDH1A1 | |
| SCHEMBL10722411 | 0.81 | AOC2 (0.55) | CES1CES2AKR1B1ALDH1A1MAPK1 | |
| SCHEMBL10724983 | 0.81 | AOC2 (0.55) | CES1CES2AKR1B1ALDH1A1MAPK1 | |
| SCHEMBL10722397 | 0.81 | AOC2 (0.55) | CES1CES2AKR1B1ALDH1A1MAPK1 | |
| SCHEMBL13884200 | 0.81 | CES1 (0.41) | CES1CES2AKR1B1TSHRALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL11133048 | 0.79 | AOC2 (0.53) | CES1CES2AKR1B1ALDH1A1MAPK1 | |
| SCHEMBL10723401 | 0.79 | BTN3A1 (0.50) | BTN3A1L3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL10723473 | 0.79 | BTN3A1 (0.50) | BTN3A1MAPK1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | claimed |
| US-4454158-A | Allyl amine MAO inhibitors | MERRELL TORAUDE ET COMPAGNIE (FR) | 1984-06-12 | — | — | US | claimed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | disclosed |
| EP-0067105-B1 | ALLYL AMINE MAO INHIBITORS | MERRELL DOW FRANCE ET CIE (FR) | 1987-09-23 | — | — | EP | disclosed |
| US-4454158-A | Allyl amine MAO inhibitors | MERRELL TORAUDE ET COMPAGNIE (FR) | 1984-06-12 | — | — | US | disclosed |
| EP-0067105-A2 | Allyl amine MAO inhibitors | MERRELL DOW FRANCE ET CIE (FR) | 1982-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | BTN3A1 3679/4885CES1 86/4885CES2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.